Institute of Pathology, Medical Faculty, University of Cologne, Cologne, Germany.
Dept of Oral Pathology, Faculty of Dentistry, Gazi University, Ankara, Turkey.
Pathologie (Heidelb). 2022 Aug;43(Suppl 1):81-85. doi: 10.1007/s00292-022-01152-7. Epub 2022 Nov 15.
Odontogenic tumors (OTs) are rare, with an estimated incidence rate of less than 0.5 cases per 100,000 per year. The causes of OTs remain unclear. Nonetheless, the majority of OTs seem to arise de novo, without an apparent causative factor. Although the etiopathogenesis of most OTs remains unclear, there have been some recent advances in understanding the genetic basis relating to specific histologies and clinical features. Molecular analyses performed by different techniques, including Sanger sequencing, next-generation sequencing, and allele-specific PCR, have uncovered mutations in genes related to the oncogenic MAPK/ERK signaling pathway. Genetic mutations in these pathway genes have been reported in epithelial and mixed OTs, in addition to odontogenic carcinomas and sarcomas. Notably, B‑RAF proto-oncogene serine/threonine kinase (BRAF) and KRAS proto-oncogene GTPase (KRAS) pathogenic mutations have been reported in a high proportion of ameloblastoma and ameloblastoma-related tumors and adenomatoid odontogenic tumors, respectively.
To discuss how molecular profiling aids in diagnostic classification of odontogenic tumors.
Molecular profiling of odontogenic tumors helps to identify patients for neoadjuvant therapies and reduces postoperative morbidity.
牙源性肿瘤(OTs)较为罕见,估计每年每 10 万人中不到 0.5 例。OTs 的病因仍不清楚。尽管大多数 OTs 似乎是从头发生的,没有明显的致病因素。尽管大多数 OTs 的病因发病机制仍不清楚,但在理解与特定组织学和临床特征相关的遗传基础方面取得了一些新的进展。通过不同技术(包括 Sanger 测序、下一代测序和等位基因特异性 PCR)进行的分子分析,揭示了与致癌 MAPK/ERK 信号通路相关的基因中的突变。除牙源性癌和肉瘤外,这些通路基因的遗传突变已在上皮和混合性 OTs 中报道。值得注意的是,B-Raf 原癌基因丝氨酸/苏氨酸激酶(BRAF)和 KRAS 原癌基因 GTP 酶(KRAS)致病性突变分别在成釉细胞瘤和与成釉细胞瘤相关的肿瘤以及腺牙源性肿瘤中报道了较高比例。
讨论分子谱分析如何有助于牙源性肿瘤的诊断分类。
牙源性肿瘤的分子谱分析有助于确定接受新辅助治疗的患者,并降低术后发病率。